Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-135,624
Closed -$4.05M 2457
2025
Q3
$4.05M Buy
+135,624
New +$4.53M 0.01% 1152
2024
Q2
Sell
-9,389
Closed -$275K 2257
2024
Q1
$275K Buy
+9,389
New +$299K ﹤0.01% 1944
2023
Q3
Hold
0
1696
2021
Q1
Sell
-16,531
Closed -$720K 1990
2020
Q4
$720K Sell
16,531
-533
-3% -$21K ﹤0.01% 1475
2020
Q3
$664K Buy
+17,064
New +$750K ﹤0.01% 1479
2019
Q2
Sell
-36,225
Closed -$1.57M 1995
2019
Q1
$1.57M Sell
36,225
-1,877
-5% -$95.6K 0.01% 1430
2018
Q4
$1.8M Sell
38,102
-19,699
-34% -$1.18M 0.01% 1259
2018
Q3
$4.32M Buy
57,801
+9,078
+19% +$625K 0.02% 1077
2018
Q2
$2.69M Buy
48,723
+6,734
+16% +$311K 0.01% 1245
2018
Q1
$1.6M Buy
+41,989
New +$1.3M 0.01% 1363

Other funds holding SRDX

Man Group's SRDX Position: Q4 2025 in Review

Man Group sold out of Surmodics (SRDX) in Q4 2025, closing a stake of 135,624 shares — an estimated $4.05M sold.

Man Group first reported a position in SRDX in Q1 2018 and held it in 9 quarters. The position peaked at $4.32M in Q3 2018. 1 fund tracked by Wall St. Rank holds SRDX as of Q4 2025.

  • Man Group reported no remaining Surmodics position as of Q4 2025 after selling out during the quarter.
  • Man Group sold 135,624 Surmodics shares in Q4 2025, an estimated $4.05M.
  • Man Group first reported a position in Surmodics in Q1 2018 and held it in 9 quarters.
  • Man Group's Surmodics position peaked at $4.32M in Q3 2018.
  • 1 fund tracked by Wall St. Rank held Surmodics as of Q4 2025.

Based on Man Group's 13F filing for Q4 2025, filed 17 Feb 2026.